Compare · MO vs PRDS
MO vs PRDS
Side-by-side comparison of Altria Group Inc. (MO) and Pardes Biosciences Inc. (PRDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MO and PRDS operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- MO is the larger of the two at $117.21B, about 178.3x PRDS ($657.5M).
- MO has hit the wire 6 times in the past 4 weeks while PRDS has been quiet.
- MO has more recent analyst coverage (19 ratings vs 3 for PRDS).
- Company
- Altria Group Inc.
- Pardes Biosciences Inc.
- Price
- $70.16+0.80%
- $2.19+1.39%
- Market cap
- $117.21B
- $657.5M
- 1M return
- -3.98%
- -
- 1Y return
- +18.94%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 6
- 0
- Recent ratings
- 19
- 3
Altria Group Inc.
Altria Group, Inc., through its subsidiaries, manufactures and sells cigarettes, oral tobacco products, and wine in the United States. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. The company also produces and sells varietal and blended table wines, and sparkling wines under the Chateau Ste. Michelle and 14 Hands names; and imports and markets Antinori, Torres, and Villa Maria Estate wines, as well as Champagne Nicolas Feuillatte in the United States. In addition, it provides finance leasing services primarily in transportation, power generation, real estate, and manufacturing equipment industries. The company sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.
Pardes Biosciences Inc.
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
Latest MO
- SEC Form 11-K filed by Altria Group Inc.
- SEC Form 11-K filed by Altria Group Inc.
- Director Kelly Ennis Debra J sold $418,318 worth of shares (5,790 units at $72.25), decreasing direct ownership by 7% to 73,809 units (SEC Form 4)
- Director Strahlman Ellen R sold $145,118 worth of shares (2,000 units at $72.56), decreasing direct ownership by 7% to 25,102 units (SEC Form 4)
- SEC Form SD filed by Altria Group Inc.
- Amendment: SEC Form 10-K/A filed by Altria Group Inc.
- U.S. Smokeless Tobacco Company Announces Plan to Modernize Manufacturing Footprint Through Facility Relocation
- Altria Group Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Strahlman Ellen R was granted 2,571 shares, increasing direct ownership by 10% to 27,102 units (SEC Form 4)
- Director Stoddart Richard S was granted 2,571 shares, increasing direct ownership by 75% to 6,010 units (SEC Form 4)
Latest PRDS
- SEC Form 15-12G filed by Pardes Biosciences Inc.
- SEC Form EFFECT filed by Pardes Biosciences Inc.
- SEC Form EFFECT filed by Pardes Biosciences Inc.
- SEC Form 4: Tananbaum James B. returned 16,813,146 shares to the company and acquired 1,000 shares
- SEC Form SC 13D/A filed by Pardes Biosciences Inc. (Amendment)
- SEC Form 4: Wiggans Thomas G closing all direct ownership in the company
- SEC Form 4: Varney Michael David closing all direct ownership in the company
- SEC Form 4 filed by Smaldone Alsup Laurie
- SEC Form 4 filed by Pottage John C Jr
- SEC Form 4: Lopatin Uri A closing all direct ownership in the company